<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13825">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365261</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD 060340</org_study_id>
    <secondary_id>ESRC 054</secondary_id>
    <nct_id>NCT00365261</nct_id>
  </id_info>
  <brief_title>Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer</brief_title>
  <official_title>Effect of Eszopiclone (Lunesta) on Sleep Disturbance and Pain in Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness of Lunesta on cancer patients who have received chemotherapy and
      who require patient controlled analgesia (PCA), specifically to assess whether Lunesta will:

        -  improve sleep thereby decreasing need for opiates via PCA

        -  improve sleep thereby decreasing pain by self report

        -  improve sleep thereby decreasing fatigue by self report
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain and fatigue are the most common symptom complaints of cancer patients. Although
      dramatic improvements have come about in recognizing and treating cancer related pain, less
      progress has been made in treating fatigue. Interventions to improve sleep may offer benefit
      in terms of pain and fatigue.

      One of the less commonly recognized side effects of opiate use is sleep disruption.

      Experimentally-induced sleep disruption lowers the threshold for detection of painful
      stimuli. Thus, although opiates are obviously helpful for pain, they do so at certain
      &quot;costs&quot;: they increase next day fatigue, constipation, and have other side effects; they
      disrupt sleep which further increases next day fatigue; and finally, by virtue of their
      sleep disruptive properties, they lower the threshold for pain stimuli.

      Cancer patients requiring chemotherapy commonly require PCA because of oral mucositis. The
      objective of this study is to assess whether opiate usage may be reduced and complaints of
      fatigue and pain be lessened if patients had better sleep.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Patient Self-report Data on Sleep, Pain, and Fatigue</measure>
    <time_frame>2 days post treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>post dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>self report of pain (1=no pain; 10=worst imaginable pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opiate Dosing From Patient Controlled Analgesia</measure>
    <time_frame>2 days post dosing</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>eszopiclone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eszopiclone</intervention_name>
    <description>eszopiclone 2 to 3 mg po at bedtime</description>
    <arm_group_label>eszopiclone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 2 to 3 mg po at bedtime</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients hospitalized for chemotherapy or blood/bone marrow
             transplant.

          2. Age 20 - 75

          3. Not currently regularly taking any prescribed sleeping pill more often than 4x/week.

          4. Can tolerate oral medication.

        Exclusion Criteria:

          1. Patients with a current history of substance abuse

          2. Patients with a history of allergic response to Lunesta.

          3. Patient who require additional oral or parenteral opioids after starting PCA opioid
             treatment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel E Dimsdale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Thornton Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dimsdale JE, Ball ED, Carrier E, Wallace M, Holman P, Mulroney C, Shaikh F, Natarajan L. Effect of eszopiclone on sleep, fatigue, and pain in patients with mucositis associated with hematologic malignancies. Support Care Cancer. 2011 Dec;19(12):2015-20. doi: 10.1007/s00520-010-1052-1. Epub 2010 Nov 30.</citation>
    <PMID>21116652</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 16, 2015</lastchanged_date>
  <firstreceived_date>August 15, 2006</firstreceived_date>
  <firstreceived_results_date>August 24, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Joel E. Dimsdale, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>fatigue</keyword>
  <keyword>sleep</keyword>
  <keyword>bone marrow transplant</keyword>
  <keyword>cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Sleep Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eszopiclone</title>
          <description>active drug</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eszopiclone</title>
          <description>active drug</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="43"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="45.52" spread="13.06"/>
                <measurement group_id="B2" value="46" spread="15.86"/>
                <measurement group_id="B3" value="45.76" spread="14.33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient Self-report Data on Sleep, Pain, and Fatigue</title>
        <time_frame>2 days post treatment</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opiate Dosing From Patient Controlled Analgesia</title>
        <time_frame>2 days post dosing</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>self report of pain (1=no pain; 10=worst imaginable pain</description>
        <time_frame>post dosing</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Eszopiclone</title>
            <description>active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain</title>
            <description>self report of pain (1=no pain; 10=worst imaginable pain</description>
            <units>pain score</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.72" spread="0.38"/>
                  <measurement group_id="O2" value="5.41" spread="0.47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Eszopiclone</title>
          <description>active drug</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <description>fatigue or drowsiness</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joel Dimsdale, M.D., Principal Investigator</name_or_title>
      <organization>University of California, San Diego</organization>
      <phone>619 543-5592</phone>
      <email>jdimsdale@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
